Pharmalot, Pharmalittle: J&J and Bayer win their first trial over alleged Xarelto harms

first_img Pharmalot, Pharmalittle: J&J and Bayer win their first trial over alleged Xarelto harms Log In | Learn More Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Top of the morning to you, and what a fine one it is. Once again, a bright, shiny sun and cool breeze are enveloping the Pharmalot campus. What better way to start the day, yes? This is especially true now that a calm has descended since the short person left for the local schoolhouse and the official mascots are on their sixth nap of the day. No naps for us, though. There is much to be done. On that note, here are some items of  interest. Have a smashing day and do keep in touch …A federal court jury found that Johnson & Johnson and Bayer did not mislead a Louisiana man and his doctors about the health risks of the Xarelto blood thinner, Bloomberg News reports. The companies, therefore, were determined not liable for his injuries and later medical problems. This was the first of more than 18,000 patient lawsuits filed against J&J and Bayer, which jointly developed Xarelto, to come to trial. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED By Ed Silverman May 4, 2017 Reprints Alex Hogan/STAT What is it? STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included?center_img GET STARTED Pharmalot About the Author Reprints Ed Silverman Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. [email protected] @Pharmalot Tags legalpharmaceuticalsSTAT+last_img

Leave a Reply

Your email address will not be published. Required fields are marked *